Analysts Set Nektar Therapeutics (NASDAQ:NKTR) Price Target at $4.08
Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. Two ...
Pharmabiz13h
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis
US FDA grants fast track designation to Nektar Therapeutics’ rezpegaldesleukin to treat moderate-to-severe atopic dermatitis: San Francisco Tuesday, February 11, 2025, 16:00 Hrs ...
Hosted on MSN11d
Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Shares of Nektar Therapeutics (NKTR) have been struggling lately and have lost 11.5% over the past four weeks. However, a ...
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Nektar Therapeutics (Nasdaq: NKTR) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric ...
FDA grants Fast Track to Nektar's atopic dermatitis drug
SAN FRANCISCO - Nektar Therapeutics (NASDAQ:NKTR) announced today that its drug candidate, rezpegaldesleukin, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for ...
Nektar receives FDA Fast Track Designation for rezpegaldesleukin
Therapeutics announced that the U.S. FDA has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and ...
Business Insider29d
Nektar Therapeutics: Promising Drug Pipeline and Strategic Expansion Drive Buy Rating
Analyst Arthur He CFA of H.C. Wainwright maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), retaining the price target of $6.50. Discover outperforming stocks and invest ...